Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial

Autor: Knoop, Ann, Lænkholm, Anne Vibeke, Jensen, M. B., Nielsen, K. V., Andersen, J., Nielsen, D., Ejlertsen, B., Danish Breast Canc Cooperative, Grp

Publikováno v: Knoop, A S, Lænkholm, A-V, Jensen, M-B, Nielsen, K V, Andersen, J, Nielsen, D, Ejlertsen, B & Danish Breast Cancer Cooperative Group 2014, ' Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial ', European journal of cancer (Oxford, England : 1990), vol. 50, no. 8, pp. 1412-21 . https://doi.org/10.1016/j.ejca.2014.02.022
Knoop, A, Lænkholm, A V, Jensen, M B, Nielsen, K V, Andersen, J, Nielsen, D, Ejlertsen, B & Danish Breast Canc Cooperative, G 2014, ' Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial ', European Journal of Cancer, vol. 50, no. 8, pp. 1412-1421 . https://doi.org/10.1016/j.ejca.2014.02.022

Background: The DBCG 77C trial compared one year of tamoxifen in postmenopausal, steroid-receptor unknown, high-risk breast cancer patients to no adjuvant systemic therapy. After a potential follow-up of 30 years we report overall efficacy of the stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d1ba0f65936cd241f1085f5321b965a
https://pure.au.dk/portal/da/publications/estrogen-receptor-progesterone-receptor-her2-status-and-ki67-index-and-responsiveness-to-adjuvant-tamoxifen-in-postmenopausal-highrisk-breast-cancer-patients-enrolled-in-the-dbcg-77c-trial(80fddd59-4cb3-4d5a-af98-93221f06dfce).html